Short answer
Labcorp (LH) filed its Q3 2025 10-Q quarterly report on Oct 31, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $3.6B (up 8.6% year over year) with net income of $261M.
Q3 2025 key financials · XBRL
- Revenue
- $3.6B
- +8.6% YoY · +1.0% QoQ
- Net income
- $261M
- +54.2% YoY · +9.8% QoQ
- Operating margin
- 11.1%
- Gross margin
- 28.8%
- EPS (diluted)
- $3.12
- +56.0% YoY · +9.9% QoQ
Source: XBRL data from the Labcorp (LH) Q3 2025 10-Q on SEC EDGAR. USD.
Labcorp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3.56B Q3 FY25, up 8.6% YoY from $3.28B; organic growth 6.2%, acquisitions 1.7%, currency 0.7%
- Operating margin Q3 FY25: Dx 16.3% vs 15.2% YoY, BLS 16.5% vs 16.4% YoY; total operating income $396.6M up 56.1% YoY
- Best segment Dx: operating income $450.4M up 16.3%, worst relative margin change BLS: 16.5% up only 0.2%
- Cash and equivalents $598.1M at Q3 FY25, down from $1.52B YoY; operating cash flow $1.03B up from $808.6M; $1.17B cash used in financing, including increased stock repurchases
- Management notes potential revenue risk from new US healthcare law (OBBBA) but expects no material impact; expects ongoing compliance with debt covenants and sufficient liquidity
Risk Factors
- No material changes in risk factors from 2024 10-K carried forward
- Pandemic impact risk persists with potential lab test volume fluctuations
- Regulatory compliance risk from evolving healthcare laws maintained without update
- Competitive pressure from new diagnostic entrants remains a key market risk
- Financial risk includes ongoing liquidity management amid capital expenditure demands
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Labcorp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.